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Abstract
Background: Children and young people (CYP) with juvenile idiopathic arthritis (JIA) are known to have impaired
health-related quality of life (HRQoL), which is improved significantly for many by treatment with methotrexate (MTX).
However, a significant proportion of CYP experience difficulties in taking MTX, which may reduce its potential benefits
for HRQoL. The aim of this research was to examine how CYP with JIA perceive MTX treatment and how this relates to
HRQoL.
Methods: CYP aged 8–16 years taking MTX for JIA completed an adapted Parent Adherence Report Questionnaire,
which contains 100 mm visual analogue scales, to assess difficulty taking MTX, adherence, frequency of negative
reactions and helpfulness of MTX. They also completed the Pediatric Quality of Life Inventory (PedsQL) Generic and
Rheumatology scales. We collected data on age, gender, JIA course, disease duration, MTX duration of use, route and
dose. Number of inflamed and limited joints were indicators of disease severity.
Results: One hundred sixteen CYP participated. Most considered MTX helpful (median 87; interquartile range (IQR)
50.75–98) and reported adherence was high (median 98; IQR 90–100). There was greater variability on scores for difficulty
(median 22; IQR 2–69) and frequency of negative reactions (median 14.5; IQR 1.25–80). Mean (S.D.) scores on the PedsQL
Physical and Psychosocial subscales were 71.63 (24.02) and 71.78 (19.59) respectively, indicating poorer HRQoL than that
reported by healthy children. After controlling for demographic and disease variables, poorer physical HRQoL was
significantly accounted for by greater difficulty in taking MTX. Poorer psychosocial HRQoL was significantly accounted for
by subcutaneous MTX administration, a lower rating of MTX helpfulness and a greater reported difficulty in taking MTX.
Conclusions: Taking MTX for JIA was viewed as helpful by most CYP but HRQoL was poorer in those who reported
greater difficulty in taking MTX.
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Background
Children and young people (CYP) with juvenile idio-
pathic arthritis (JIA) are known to have impaired health-
related quality of life (HRQoL), particularly on measures
of the physical domain [1, 2]. Although this is improved
significantly for many CYP by treatment with metho-
trexate (MTX) [3] and biologic therapies [4], HRQoL
can remain suboptimal [5]. Higher pain scores and
poorer physical function are important predictors of
poorer HRQoL in JIA [6] but variability in HRQoL is
not explained purely by these factors [7]. For example,
Seid et al. [5] found that many CYP with no or mild
symptoms still report impaired HRQoL.
A factor that may influence HRQoL in JIA is how CYP
experience their treatment. Although MTX has been
found to improve HRQoL in JIA [3], CYP may experi-
ence side effects such as nausea and vomiting and pro-
cedural distress [8, 9]. Approximately half of CYP who
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take MTX for JIA are reported to experience difficulties.
We have previously reported proxy data from mothers
of CYP with JIA which found that feeling sick after tak-
ing MTX and anxiety about injections were related to
poorer HRQoL [9]. Such proxy reports are essential in
child health, particularly in relation to younger children,
but given the differences found between patient and
proxy reports on other measures [10–12], CYP’s own re-
ports of their experiences of taking medication for JIA
are also needed.
We are aware of two studies in JIA that have examined
the relationship between CYP’s views about their treat-
ment and their HRQoL. Seid et al. [7] found a relation-
ship between greater self-reported treatment problems
assessed with the PedsQL Rheumatology Module [2] and
poorer physical and psychosocial HRQoL. A study which
examined HRQoL in JIA using self-reports from CYP
aged 8 years and over, identified ‘subjective burden of
medication use’ as a predictor of psychosocial HRQoL in
JIA [13]. Neither of these studies asked specifically about
MTX and we are not aware of any research that has ex-
amined CYP’s own reports of taking MTX and how this
impacts on their HRQoL. The aim of this study was to
examine how CYP with JIA perceive their MTX treat-
ment and how this relates to their HRQoL.
Methods
Design
A cross-sectional design was used. Data were collected
as part of the Childhood Arthritis Response to Medica-
tion Study (CHARMS), which investigates factors that
influence response to MTX or anti-TNF treatment for
JIA. This study examines genetic, immunological and
psychological aspects of response to medication and re-
cruits CYP who are about to start taking methotrexate
(MTX) or anti-TNF, are taking MTX at the time of re-
cruitment or have taken MTX in the past. The study
methodology has been described in detail elsewhere [9].
Participants
Participants were recruited from Great Ormond Street
Hospital for Children and the Adolescent Rheumatology
service at University College Hospital, London, UK be-
tween May 2006 and May 2008. Patients were eligible to
take part in the CHARMS study if they had a diagnosis
of JIA defined by International League of Associations
for Rheumatology (ILAR) criteria [14]. Although
CHARMS recruits patients of any age, only patients
aged 8 years and over completed questionnaires about
their experience of MTX. Not all CYP in the study were
still taking MTX at the time the study questionnaires
were completed. As some CYP may have ceased taking
MTX because they were well but others may have
ceased due to intolerance, this analysis is restricted to
those CYP who were taking MTX at the time of ques-
tionnaire completion to help ensure a more homoge-
neous sample.
Procedures
Parents were approached to take part in the
CHARMS study at a routine out-patient appointment.
Written informed consent was obtained from at least
one parent and age-appropriate written assent was
obtained from the patient. CYP completed the ques-
tionnaires described below during waiting time in the
clinic. They were given the option to complete the
questionnaires independently or for the researcher to
read through the questions for them. The researcher
was also available to answer any queries from CYP
who chose to complete the questionnaires independ-
ently. Parents did not assist CYP with questionnaire
completion.
Ethics, consent and permissions
The study had full ethical approval from the Institute of
Child Health/GOSH Local Research Ethics Committee,
reference 05/Q0508/95. All participants gave full, in-
formed written consent (parental consent and age ap-
propriate child/young person assent). The study
conforms to the principles outlined in the Declaration of
Helsinki.
Measures
Participants completed the following questionnaires:
 Views about MTX were assessed by adapting the
Parent Adherence Report Questionnaire (PARQ)
[15] so that the questions were addressed to the
CYP instead of the parent. CYP indicated on a
100 mm horizontal VAS i) their level of difficulty
in taking MTX with endpoints very easy/very
hard; ii) how often they take MTX as prescribed
with endpoints never/always; iii) negative
reactions such as crying in response to taking
MTX with endpoints never/always and iv) their
opinion of the helpfulness of MTX for their
arthritis with endpoints not helpful/very helpful.
A mean of questions i) – iii) is calculated to
provide an ‘ability to take’ score. Higher scores
represent greater perceived ability to take and
greater perceived helpfulness.
 HRQoL was assessed using the Pediatric Quality of
Life Inventory (PedsQL) Generic and Rheumatology
scales [2]. The generic scale provides physical and
psychosocial composite scores. The rheumatology
scale has 5 subscales: pain and hurt; daily activities;
treatment; worry; communication. The composite
and subscale scores are each transformed to 0–100
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scores as specified by Varni et al. (2002) [2], where a
higher score represents better HRQoL.
 We also collected data on the child’s age, gender, JIA
type according to ILAR criteria [14] (systemic,
oligoarticular persistent, oligoarticular extended,
polyarticular RF-, polyarticular RF+, psoriatic,
enthesitis-related arthritis (ERA), undifferentiated)
disease duration, MTX duration of use, route and
dose. The number of inflamed/active and limited
joints was recorded as indicators of current disease
activity.
Statistical analysis
Statistical analysis was performed in IBM SPSS Statis-
tics 22.
Medians and interquartile ranges (IQR) were calcu-
lated for scores on the PARQ. To examine the hypoth-
esis that CYP’s views of MTX would account for some
of the variance in HRQoL measured with the PedsQL,
the relationship between variables was examined initially
by correlations (Pearson r correlations for continuous
variables, Spearman’s rho (rs) for ordinal variables). In
the case of categorical independent variables (e.g. gen-
der), differences in HRQoL between categories were ex-
amined by t-test or analysis of variance (ANOVA), as
applicable. As expected, we recruited small numbers of
CYP with the lower prevalence JIA types (psoriatic = 6;
ERA = 7; undifferentiated = 2); therefore we classified
participants into whether they had an oligoarticular or
polyarticular course, that is the number of joints that
had been involved up to the time of the study (4 or less,
more than 4 respectively).
To examine which variables accounted for most
variance in HRQoL, all significant variables identified
from the univariate analyses were included in hier-
archical multiple regressions using enter method and
a level of p < .05 as an entry criterion.
Two regression analyses were performed, one for
the Physical and one for the Psychosocial summary
scales of the Generic PedsQL. The independent vari-
ables were entered into the regression in blocks in
the following order: 1. Demographic variables; 2. Dis-
ease variables; 3. MTX-related variables. This order
was used because it enables examination to be made
as to whether experience of MTX added to the ex-
planation of quality of life once disease severity had
been taken into account.
Results
One hundred sixteen CYP who were taking MTX at
the time of study recruitment completed the study
questionnaires. Sample characteristics are shown in
Table 1. As expected in JIA, the majority of CYP
were female, and for most, their JIA had taken a
polyarticular course, affecting 5 or more joints. A
small majority of CYP (54.3 %) were taking MTX
subcutaneously at time of assessment.
CYP’s views about MTX are shown in Fig. 1, which
reports the median and inter quartile range (IQR)
scores on the PARQ. Self-reported adherence was
very high among most CYP, with a median (IQR) of
98 (90–100) on the 100 mm scale, however 20
(17.4 %) scored below 80, and of these, 9 (7.8 %)
scored below 50. Scores on the other items of the
PARQ showed greater variability. A quarter of CYP
scored 69 or above on the 100 mm scale for level of
difficulty in taking MTX and 80 or above on the
100 mm scale for frequency of negative reactions to
MTX. Most CYP rated MTX as helpful with half
scoring 87 or above on level of helpfulness however a
quarter scored on or below the midpoint of the scale.
Scores on the PedsQL Generic Scale and Rheuma-
tology Module are shown in Table 2. Mean scores on
the Rheumatology Module and Physical and Psycho-
social subscales were similar to those recorded by the
scale's developers in children with JIA [2]. Scores
were poorer than those reported by a healthy UK
sample, aged 8–18 years, of 88.51 (11.62) and 81.84
(13.21) respectively [16].
In univariate analysis, the independent variables that
were associated with better Physical HRQoL were: male
gender (t = 2.12, df = 114, p < 0.05); fewer active joints
(rs = −0.22, p < 0.05); greater perceived ability to take
MTX (r = 0.38, p < 0.005) and greater perceived helpful-
ness of MTX (r = 0.30, p = 0.001). The independent vari-
ables that were associated with better Psychosocial
HRQoL were: fewer active joints (rs = −0.23, p < 0.05);
oral administration of MTX (t = 2.27, df = 113, p < 0.05),
greater perceived ability to take MTX (r = 0.38, p <
0.005) and greater perceived helpfulness of MTX (r =
0.27, p < 0.005).
Multivariate analyses of the relation between experi-
ences of MTX and physical and psychosocial HRQoL
are shown in Table 3. CYP’s perceptions of MTX
made a small but statistically significant contribution
to explaining variability in HRQoL. MTX-related vari-
ables explained an additional 9 % and 16 % respect-
ively in physical and psychosocial HRQoL after
controlling for gender and disease activity, as shown
by the change in cumulative adjusted R2 in Table 3.
After controlling for demographic and disease vari-
ables, poorer physical HRQoL was significantly
accounted for by greater reported difficulty in taking
MTX. Poorer psychosocial HRQoL was significantly
accounted for by subcutaneous MTX administration,
a lower rating of MTX helpfulness and a greater re-
ported difficulty in taking MTX.
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Discussion
This is the first study of which we are aware that has
reported CYP’s views about taking MTX for JIA in
relation to their HRQoL. In the multiple regression
analyses MTX-related variables made an independent
contribution to explaining variance in physical and psy-
chosocial HRQoL after controlling for demographic and
disease-related variables. Physical HRQoL was poorer in
those who reported greater difficulty in taking MTX. Psy-
chosocial HRQoL was poorer in those who: took MTX
subcutaneously rather than orally; reported a greater level
of difficulty in taking MTX and reported a lower level of
helpfulness of MTX. Our findings concur with those of
Seid et al. 2014 [7] and Haverman et al. 2012 [13], which
found that self-reported problems with treatment were re-
lated to poorer HRQoL. The current study found that
MTX-related factors were important in explaining both
physical and psychological HRQoL as measured by the
PedsQL.
We have previously reported findings from the mothers
of CYP in the CHARMS study [9]. Approximately half of
CYP were reported by their mothers to have experienced
Table 1 Sample characteristics
n 116
Gender, n (%) female 77 (66.4)
Age in years when questionnaire data completed, mean (S.D.) 11.9 (2.2)
JIA course, n (%)
systemic 14 (12.1)
oligoarticular 11 (9.5)
polyarticular 91 (78.4)
Disease duration in years, mean (S.D.) 5.5 (3.4)
Current disease severity, median, range, (IQR)
Number of active joints (data for n = 111) 0, 0-10, 0-2
Number of limited joints (data for n = 108) 1, 0–32, (0–3)
Duration of MTX use in years, median (IQR) 2 (1–5)
MTX current route
Oral, n (%) 53 (45.7)
Subcutaneous, n (%) 63 (54.3)
Current MTX dose in mg/m2/week, median (IQR) 15 (12.5 – 20.0)
Fig. 1 Shows boxplots of scores on the adapted PARQ measure
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MTX side effects and/or procedural anxiety regarding in-
jections or blood tests. The child assessment we report in
this paper used a simpler, less detailed measure of MTX-
related difficulties, so the results are not directly compar-
able but the finding of a relationship between problems
taking MTX and poorer HRQoL is consistent across the
respondents.
Receiving MTX to treat JIA has been shown to have a
beneficial effect on CYP’s HRQoL [3], however those
CYP who experience difficulty in taking MTX may not
gain the full benefit. This study has shown that although
most CYP rated MTX as helpful and reported high ad-
herence, a significant minority report difficulties taking
MTX and these difficulties were associated with poorer
HRQoL. Clinicians who ask directly about CYPs’ experi-
ences of taking MTX may be able to further enhance the
HRQoL of their patients by offering treatments to help
address these difficulties.
Psychosocial HRQoL was poorer in CYP taking MTX
by subcutaneous rather than oral route. The data for this
study were collected before the introduction of the
Metoject pen. It would be of interest to examine
whether use of the pen has an impact on pain and/or
anxiety and any consequent impact on HRQoL.
The study has several limitations. As the study is
cross-sectional, the direction of causation is unclear
therefore it is possible that those children with poorer
HRQoL have a generally more negative outlook and
perceive MTX more negatively. We have however
controlled for disease activity in the analysis (see
Table 3) which indicates that experience of MTX is
an independent predictor of HRQoL after taking dis-
ease activity into account i.e. it is not the case that
the findings are explained simply by CYP with more
active joints perceiving MTX more negatively.
The study reports HRQoL at a single time-point in
those CYP currently taking MTX. Although the CHARMS
study included CYP who were no longer taking MTX, the
study was not examining reasons for stopping MTX and
therefore this information was not recorded. It is possible
that HRQoL would have varied in those CYP who stopped
MTX due to intolerance or remission but we were unable
to examine these differences. We therefore limited the
analyses in this paper to CYP currently taking MTX. It
would be informative to examine CYPs’ experiences of
taking MTX and HRQoL over time from when they first
take the medication.
As the study respondents are CYP, it is limited to those
aged eight years and over. However, a strength of the
CHARMS study is that we collected data from both
parents and CYP so our related publication reporting
mothers’ views was able to include proxy reports for
younger children. A limitation of using a VAS to measure
participants’ views about MTX is that it is not clear what
cut-off scores on the 100 mm scales should be considered
to signify, for example, mild, moderate and severe prob-
lems in taking MTX and therefore what percentage of
CYP would fall into each category. The CYP in this study
were already being treated with MTX for varying dura-
tions when they were recruited therefore it was not pos-
sible to control for level of response to MTX in our
analysis. We did, however, include an indicator of disease
severity in the number of active and limited joints.
Table 2 Participant scores on the Generic Core Scales and
Rheumatology Module of the Pediatric Quality of Life Inventory
(PedsQL)
PedsQL, Generic Scale, mean (S.D.)a
Physical 71.63 (24.02)
Psychosocial 71.78 (19.59)
PedsQL, Rheumatology Module, mean (S.D.) a
Pain and hurt 65.80 (25.94)
Daily activities 85.91 (19.77)
Treatment 69.51 (21.65)
Worry 67.17 (24.16)
Communication 64.51 (28.97)
ascale 0 – 100, higher score = better HRQoL
Table 3 Multiple regression analyses of variables related to health-related quality of life
PedsQL Physical PedsQL Psychosocial
Variables β t Cumulative Adjusted R2 β t Cumulative Adjusted R2
Demographics: 0.03
Gender 0.149 −1.645 - -
Disease activity: 0.05 0.03
Active joints 0.110 −1.195 −0.126 −1.422
MTX: 0.14 0.19
Subcutaneous route - - −0.197 −2.216*
PARQ Ability to take 0.256 2.688** 0.270 2.912**
PARQ Helpfulness 0.159 1.732 0.217 2.408*
*p < 0.05, **p < 0.01
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Conclusions
In conclusion, this analysis of CYP’s views about and ex-
perience of taking MTX supports the findings from our
reports of mothers of CYP with JIA that MTX is viewed
as helpful by most CYP but HRQoL is poorer in those
who report greater difficulty in taking MTX.
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